From: Review of icatibant use in the Winnipeg Regional Health Authority
Category | Stratification | Time to OSR, median, hours | p-value (*< 0.05), pairwise | Time to FCO, median, hours | p-value (*< 0.05), pairwise |
---|---|---|---|---|---|
History or diagnosis | HAE ACEI-induced | 1.13 4.86 | 0.05 | 3.50 19.53 | 0.02* |
Atopy None | 8.35 7.94 | 0.40 | 19.53 7.94 | 0.40 | |
Smoking None | 1.00 3.20 | 0.60 | 9.75 7.38 | 0.70 | |
Body system | Face/oropharolarynx involvement None | 2.17 1.00 | 0.50 | 8.93 2.50 | 0.10 |
Abdominal involvement None | 1.25 2.17 | 0.71 | 2.92 14.64 | 0.05 | |
Cutaneous involvement None | 1.00 1.43 | 0.30 | 18.83 7.75 | 0.40 | |
Initial treatment | Antihistamine None | 3.13 1.13 | 0.40 | 14.63 4.08 | 0.08 |
Epinephrine None | 4.08 1.34 | 0.90 | 19.53 5.53 | 0.10 | |
Glucocorticoids None | 4.08 1.00 | 0.20 | 19.53 3.50 | 0.03* | |
C1-INH None | 3.20 1.13 | 0.70 | 6.47 7.75 | 0.90 | |
FFP None | 4.53 1.14 | 0.40 | 9.75 5.83 | 0.30 |